<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Sweeps - Silver Star Spirits]]></title><description><![CDATA[Rivermark]]></description><link>https://www.rivermarkmedical.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Fri, 20 Nov 2026 19:28:36 GMT</lastBuildDate><atom:link href="https://www.rivermarkmedical.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[RIVERMARK MEDICAL COMPLETES ENROLLMENT IN RAPID III PIVOTAL STUDY OF THE FLOSTENT™ SYSTEM AND STRENGTHENS LEADERSHIP WITH TWO KEY APPOINTMENTS]]></title><description><![CDATA[Urology industry veteran Steve Blum joins Board of Directors; Axonics co-founder and former CEO Raymond W. Cohen named Senior Advisor MILWAUKEE, Nov. 17, 2026 /PRNewswire/ -- Rivermark Medical, a medical device company developing innovative treatments for benign prostatic hyperplasia (BPH), today announced the completion of enrollment in its RAPID III pivotal clinical study of the FloStent™ System.  Rivermark also named Steve Blum an independent member of its Board of Directors and Raymond W....]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-completes-enrollment-in-rapid-iii-pivotal-study-of-the-flostent-system-and-streng</link><guid isPermaLink="false">6afc6fdc3a8fe54204709073</guid><pubDate>Tue, 17 Nov 2026 15:18:16 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/587ac2_7ce3ff551f154b959ad2837ce314d4a2~mv2.jpg/v1/fit/w_1000,h_848,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>michelansaragmailcom</dc:creator></item><item><title><![CDATA[Andera Partners Leads $20 MillionSeries D Financing in RivermarkMedical.]]></title><description><![CDATA[The FloStent™ System Promises to Redefine the BPH Care Pathway.  Andera Partners, a leading European venture capital and private equity firm, today announced it led a $20 million Series D financing in Rivermark Medical, Inc., a urology-focused medical device company committed to redefining benign prostatic hyperplasia (BPH) treatment through simple, innovative solutions. The round also included participation from existing investors and an unnamed strategic investor.  Proceeds will be used to...]]></description><link>https://www.rivermarkmedical.com/post/andera-partners-leads-20-millionseries-d-financing-in-rivermarkmedical</link><guid isPermaLink="false">6aee51ccb4d13b3b69c0241e</guid><pubDate>Wed, 13 May 2026 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/587ac2_1f340549fe504a698f7a5393aa2202d4~mv2.jpg/v1/fit/w_1000,h_691,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>michelansaragmailcom</dc:creator></item><item><title><![CDATA[RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT® SYSTEM]]></title><description><![CDATA[Rivermark Medical, a urology-focused medical device company committed toredefining benign prostatic hyperplasia (BPH) treatment through simple,innovative solutions, today announced the enrollment of the first patient inits RAPID III clinical study. RAPID III is a prospective, multicenter,randomized pivotal clinical trial (NCT06849258) designed to evaluate the safetyand effectiveness of the FloStent™ System in men experiencing lower urinarytract symptoms caused by BPH. The first procedure...]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-announces-first-patient-enrolled-in-rapid-iii-clinical-study-evaluating-the-floste</link><guid isPermaLink="false">6a58e84948b343e14f132ad5</guid><pubDate>Tue, 01 Apr 2025 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/587ac2_3fcab7de4665411f85c8754b6e6aec50~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Greg Borecki</dc:creator></item><item><title><![CDATA[Rivermark Medical Closes $30 Million Series C Financing to Advance Development of FLOSTENT™ System for Benign Prostatic Hyperplasia]]></title><description><![CDATA[Milwaukee, WI – Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), today announced the close of a $30 million Series C financing round. The round was led by American Century Investments (ACI) including new investors Venture Investors Health Fund, Time BioVentures and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC. Funds will advance the...]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-closes-30-million-series-c-financing-to-advance-development-of-flostent-system-f</link><guid isPermaLink="false">6a58e8cf01e576df51c75904</guid><pubDate>Thu, 17 Oct 2024 05:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_8dcdc5eba67e46a5be9cae5dfed8b13d~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Greg Borecki</dc:creator></item><item><title><![CDATA[Rivermark Medical Announces Completion of Expanded Indication Study for the Flostent System]]></title><description><![CDATA[Clinical study evaluates the opportunity to treat patients suffering urinary retention due to benign prostatic hyperplasia Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company’s FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures...]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-announces-completion-of-expanded-indication-study-for-the-flostent-system</link><guid isPermaLink="false">6a58e92501e576df51c759ce</guid><pubDate>Mon, 08 Jan 2024 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_eb4a416822ab445d9f5cdd73c68f8a8b~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>.</dc:creator></item><item><title><![CDATA[Rivermark Medical Announces Fully Enrolled Multi-center OUS Clinical Trial for Innovative Benign Prostatic Hyperplasia Device]]></title><description><![CDATA[DECEMBER 7, 2023 Clinical programs supported by close of oversubscribed Series B FinancingMILWAUKEE – December 7, 2023 – Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the full enrollment of its RAPID-II clinical trial, a multi-center OUS clinical trial with sites in Australia, New Zealand, and Mexico. The trial is funded by the company’s oversubscribed Series B financing which closed earlier this year...]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-announces-fully-enrolled-multi-center-ous-clinical-trial-for-innovative-benign-pro</link><guid isPermaLink="false">6abc0cef94de20867afd74a4</guid><pubDate>Thu, 07 Dec 2023 20:10:01 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/b0f3919d3ce8417b8f133eb2844f5997.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>.</dc:creator></item><item><title><![CDATA[Rivermark Medical announces successful first-in-human use of its Flostent System For Symptomatic BPH]]></title><description><![CDATA[Company to expand clinical program as all treated patients experienced rapid symptom improvementMILWAUKEE, Jan. 10, 2023 /PRNewswire/--Rivermark MedicalTM, a company dedicated to developing first-line device therapy for benign prostatic hyperplasia (BPH), announced today the successful first-in-human (FIH) use of its FloStentTM System as part of the Company's RAPID-1 FIH clinical study. The procedures were performed on 15 patients by Principal Investigator (PI) Dr. Ingrid Perscky Arravanti...]]></description><link>https://www.rivermarkmedical.com/post/rivermark-medical-announces-successful-first-in-human-use-of-its-flostent-system-for-symptomatic-bph</link><guid isPermaLink="false">6a58e96c48b343e14f132d31</guid><pubDate>Tue, 10 Jan 2023 06:00:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_a4a8ce10cd884a52a42b6518c527525b~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>.</dc:creator></item></channel></rss>